Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 32Terminated 5Withdrawn 3Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 29NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Filgrastim × Clear all
NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡